1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Demographic and clinical characteristics of study sample
Demographics/Characteristics 
No. of subjects 24
No. of lesions 306
Lesions per subject analyzed (median) (range) 12 (2–29)
Age (mean) (SD) (yr) 44.3 (10.0)
Sex (No.) (%) 
    Female 12 (50%)
    Male 12 (50%)
Disease duration (mean) (SD) (yr) 11.2 (7.6)
Clinical phenotype (No.) (%) 
    Relapsing-remitting 21 (88%)
    Secondary-progressive 2 (8%)
    Primary-progressive 1 (4%)
On MS treatment (No.) (%) 19 (79%)
EDSS score (median) (range) 3.0 (1.5–6.5)
MFIS score (mean) (SD) 37.7 (19.3)
9-HPT, dominant hand (mean) (SD) 23.0 (6.6) seconds
9-HPT, nondominant hand (mean) (SD) 27.7 (17.9) seconds
Timed 25-ft walk (mean) (SD) 5.3 (2.4) seconds
PASAT-3 score (mean) (SD) 46.3 (9.8)
MSFC z score (mean) (SD) −0.27 (1.54)
Note:—9-HPT indicates Nine Hole Peg Test; PASAT-3, Paced Auditory Serial Addition Test, 3-second delay.